Gadolinium periconceptional exposure: pregnancy and neonatal outcome
M De Santis1, G Straface, A F Cavaliere
1Telefono Rosso - Teratology Information Service, Department of Obstetrics and Gynaecology, Catholic University of Sacred Heart, Rome, Italy.
Background:
Gadolinium derivatives are ionic paramagnetic contrast agents used to enhance magnetic resonance images, labeled as a pregnancy category C by the Food and Drug Administration because of a lack of epidemiological studies concerning first-trimester exposure.
Methods:
Prospective cohort study to determine whether gadolinium derivatives exposure in periconceptional period is a risk factor for pregnancy or fetal development.
Results:
We report the outcome of 26 pregnant women exposed to gadolinium derivatives in the first trimester without adverse effect on pregnancy and neonatal outcome.
Conclusions:
Currently, this study represents the only prospective investigation of gadolinium derivatives in pregnancy, but more data are necessary to exclude a teratogenic risk.
Related Concept Videos
01:07Teratogenicity
01:14Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...